Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
$0.02
+7.4%
$0.02
$0.01
$3.47
$1.14M1.57281,029 shs310,800 shs
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$0.09
$0.11
$0.05
$0.34
$5.70M1.614,134 shs33 shs
GRNV
GreenVision Acquisition
$10.89
$7.70
$25.30
$37K0.07105,738 shs1.54 million shs
HemaCare Co. stock logo
HEMA
HemaCare
$25.31
+0.6%
$25.31
$8.62
$26.23
$346.52M1.4739,950 shs5,400 shs
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$8.06
+2.8%
$8.83
$5.90
$12.01
$312.41M1.51159,168 shs136,441 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
0.00%0.00%0.00%-14.99%-99.11%
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
-0.01%-12.29%-10.58%-3.36%-72.09%
GRNV
GreenVision Acquisition
0.00%0.00%0.00%-63.92%-99.31%
HemaCare Co. stock logo
HEMA
HemaCare
0.00%0.00%0.00%0.00%0.00%
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
-0.51%-3.69%-14.32%-6.22%-33.39%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
GRNV
GreenVision Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/AN/AN/AN/AN/AN/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/AN/AN/AN/A
GRNV
GreenVision Acquisition
N/AN/AN/AN/A
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/AN/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
$1.27M0.90N/AN/A($14.93) per share0.00
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$18.39M0.31N/AN/A($0.69) per share-0.13
GRNV
GreenVision Acquisition
N/AN/AN/AN/A$0.70 per shareN/A
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/AN/AN/AN/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$183.01M1.71$0.85 per share9.45$2.96 per share2.72

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%5/10/2024 (Estimated)
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
-$10.62M-$0.10N/AN/A-16.66%N/A-9.73%N/A
GRNV
GreenVision Acquisition
-$510KN/A0.00N/AN/AN/A-54.82%-2.65%N/A
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/A0.00N/AN/AN/AN/AN/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
$10.24M$0.2631.00N/A5.60%9.59%7.09%5/13/2024 (Estimated)

Latest VMD, HEMA, BXRX, GRNV, and EMMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/6/2024Q4 2023
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/A$0.09+$0.09$0.09N/A$50.74 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/AN/AN/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/AN/AN/AN/AN/A
GRNV
GreenVision Acquisition
N/AN/AN/AN/AN/A
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/AN/AN/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
N/A
0.07
0.07
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A
0.15
0.12
GRNV
GreenVision Acquisition
N/A
0.29
0.29
HemaCare Co. stock logo
HEMA
HemaCare
N/AN/AN/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
0.05
1.19
1.05

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
9.05%
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
7.42%
GRNV
GreenVision Acquisition
N/A
HemaCare Co. stock logo
HEMA
HemaCare
N/A
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
74.24%

Insider Ownership

CompanyInsider Ownership
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
0.10%
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
35.00%
GRNV
GreenVision Acquisition
42.90%
HemaCare Co. stock logo
HEMA
HemaCare
26.20%
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
19.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Baudax Bio, Inc. stock logo
BXRX
Baudax Bio
952.46 million52.41 millionNot Optionable
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
5461.85 million40.20 millionNot Optionable
GRNV
GreenVision Acquisition
N/A3.35 millionN/ANot Optionable
HemaCare Co. stock logo
HEMA
HemaCare
N/A13.69 millionN/ANot Optionable
Viemed Healthcare, Inc. stock logo
VMD
Viemed Healthcare
99638.76 million31.32 millionNot Optionable

VMD, HEMA, BXRX, GRNV, and EMMA Headlines

SourceHeadline
Viemed Healthcare Announces Date and Time for Conference CallViemed Healthcare Announces Date and Time for Conference Call
globenewswire.com - April 23 at 9:00 AM
Viemed Healthcare: Long-Term Bull Remains Intact But Patience RequiredViemed Healthcare: Long-Term Bull Remains Intact But Patience Required
seekingalpha.com - April 17 at 8:27 AM
Triasima Portfolio Management inc. Trims Stock Position in Viemed Healthcare, Inc. (NASDAQ:VMD)Triasima Portfolio Management inc. Trims Stock Position in Viemed Healthcare, Inc. (NASDAQ:VMD)
marketbeat.com - April 14 at 11:11 AM
Analysts Offer Insights on Healthcare Companies: Silk Road Medical (SILK) and Viemed Healthcare (VMD)Analysts Offer Insights on Healthcare Companies: Silk Road Medical (SILK) and Viemed Healthcare (VMD)
markets.businessinsider.com - April 3 at 2:01 PM
Viemed gets controlling interest in Alabama HMEViemed gets controlling interest in Alabama HME
hmenews.com - April 2 at 2:00 PM
Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama HealthViemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health
globenewswire.com - April 2 at 9:00 AM
Viemed Healthcare, Inc. (VMD) Q4 2023 Earnings Call TranscriptViemed Healthcare, Inc. (VMD) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 9 at 4:47 PM
VMD stock wins price target raise at BeaconVMD stock wins price target raise at Beacon
cantechletter.com - March 7 at 4:59 PM
Viemed Healthcare Inc (VMD) Reports Record Financial Results for 2023Viemed Healthcare Inc (VMD) Reports Record Financial Results for 2023
finance.yahoo.com - March 7 at 3:41 PM
VMD Stock Earnings: Viemed Healthcare Misses EPS, Beats Revenue for Q4 2023VMD Stock Earnings: Viemed Healthcare Misses EPS, Beats Revenue for Q4 2023
msn.com - March 6 at 11:30 PM
Viemed Healthcare Announces Record 2023 Financial ResultsViemed Healthcare Announces Record 2023 Financial Results
globenewswire.com - March 6 at 5:00 PM
Heres what Wall Street expects from Viemed Healthcares earnings reportHere's what Wall Street expects from Viemed Healthcare's earnings report
markets.businessinsider.com - March 5 at 10:59 AM
Viemed Healthcare Inc.Viemed Healthcare Inc.
wsj.com - February 22 at 9:29 PM
Viemed Healthcare Announces Date and Time for Conference CallViemed Healthcare Announces Date and Time for Conference Call
globenewswire.com - February 20 at 4:30 PM
Investors in Viemed Healthcare (NASDAQ:VMD) have seen decent returns of 83% over the past five yearsInvestors in Viemed Healthcare (NASDAQ:VMD) have seen decent returns of 83% over the past five years
finance.yahoo.com - January 10 at 7:09 AM
Should You Hold Viemed Healthcare (VMD)?Should You Hold Viemed Healthcare (VMD)?
finance.yahoo.com - December 26 at 9:21 AM
Are Investors Undervaluing Viemed Healthcare, Inc. (NASDAQ:VMD) By 46%?Are Investors Undervaluing Viemed Healthcare, Inc. (NASDAQ:VMD) By 46%?
finance.yahoo.com - December 24 at 11:59 AM
Viemed Healthcare Inc Ordinary SharesViemed Healthcare Inc Ordinary Shares
morningstar.com - December 21 at 10:01 AM
Is Viemed Healthcare, Inc. (TSE:VMD) Trading At A 50% Discount?Is Viemed Healthcare, Inc. (TSE:VMD) Trading At A 50% Discount?
finance.yahoo.com - November 18 at 8:51 AM
Viemed Healthcare Inc Ordinary Shares VMDViemed Healthcare Inc Ordinary Shares VMD
morningstar.com - November 11 at 5:04 AM
Viemed Healthcare to Present at Stifel 2023 Healthcare ConferenceViemed Healthcare to Present at Stifel 2023 Healthcare Conference
finance.yahoo.com - November 7 at 9:40 AM
Viemed Healthcare, Inc.: Viemed Healthcare Announces Record Third Quarter 2023 Financial ResultsViemed Healthcare, Inc.: Viemed Healthcare Announces Record Third Quarter 2023 Financial Results
finanznachrichten.de - November 2 at 7:42 AM
Viemed Healthcare Announces Record Third Quarter 2023 Financial ResultsViemed Healthcare Announces Record Third Quarter 2023 Financial Results
finance.yahoo.com - November 1 at 6:12 PM
Viemed Healthcare Q3 2023 Earnings PreviewViemed Healthcare Q3 2023 Earnings Preview
msn.com - October 31 at 6:12 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Baudax Bio logo

Baudax Bio

NASDAQ:BXRX
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.
Emmaus Life Sciences logo

Emmaus Life Sciences

OTCMKTS:EMMA
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

GreenVision Acquisition

NASDAQ:GRNV
As of April 1, 2021, operates as a subsidiary of Helbiz, Inc..
HemaCare logo

HemaCare

OTCMKTS:HEMA
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.
Viemed Healthcare logo

Viemed Healthcare

NASDAQ:VMD
Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.